In the last trading session, 3.09 million shares of the Humacyte Inc (NASDAQ:HUMA) were traded, and its beta was 1.43. Most recently the company’s share price was $4.84, and it changed around $0.0 or -0.10% from the last close, which brings the market valuation of the company to $621.47M. HUMA currently trades at a discount to its 52-week high of $9.97, offering almost -105.99% off that amount. The share price’s 52-week low was $2.35, which indicates that the current value has risen by an impressive 51.45% since then. We note from Humacyte Inc’s average daily trading volume that its 10-day average is 3.59 million shares, with the 3-month average coming to 2.93 million.
Humacyte Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended HUMA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Humacyte Inc is expected to report earnings per share of -0.25 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA has showed a red trend with a performance of -0.10% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.82 on recent trading dayincreased the stock’s daily price by 16.84%. The company’s shares are currently up 70.25% year-to-date, but still down -16.35% over the last five days. On the other hand, Humacyte Inc (NASDAQ:HUMA) is -0.51% down in the 30-day period. We can see from the shorts that 17.25 million shares have been sold at a short interest cover period of 5.35 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 19.33% from its current value. Analyst projections state that HUMA is forecast to be at a low of $5 and a high of $10.
Humacyte Inc (HUMA) estimates and forecasts
Humacyte Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -23.62 percent over the past six months and at a -18.69% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 1.39% in revenue this quarter, and will report an increase of 0.87% in the next quarter.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 214.29k in revenue for the current quarter. 4 analysts expect Humacyte Inc to make 2.58M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at ∞%.
HUMA Dividends
Humacyte Inc’s next quarterly earnings report is expected to be released on 2025-Mar-20.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 27.73% of Humacyte Inc shares, and 29.27% of them are in the hands of institutional investors. The stock currently has a share float of 40.50%. Humacyte Inc stock is held by 192.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 6.5961% of the shares, which is about 7.14 million shares worth $34.27 million.
VANGUARD GROUP INC, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
